DiscoveRx Corporation Announces the Expansion of KINOMEscan’s Largest Commercially Available Kinase Panel

FREMONT, Calif.--(BUSINESS WIRE)-- DiscoveRx announced today the successful expansion of its industry leading KINOMEscan™ kinase assay panel for kinase inhibitor profiling and screening services. Now with 451 kinase assays in the scanMAX™ assay panel, which will be available for global customers by mid-June 2011, DiscoveRx continues to maintain its leadership position by offering the largest validated kinase panel for screening and profiling services. This milestone achievement reaffirms DiscoveRx’s continued commitment to invest in developing innovative new products and solutions for the drug discovery community.

“DiscoveRx has always believed in investing in innovation. First with leading PathHunter® cell-based and HitHunter® biochemical assays utilizing its β-galactosidase enzyme fragment complementation platform and now with KINOMEscan high-throughput kinase inhibitor and profiling platform. Today’s drug discovery efforts demand a high quality, highly differentiated solution portfolio and DiscoveRx is committed to providing this through innovation, quality and service to its customers,” commented Pyare Khanna, Ph.D., President & CEO of DiscoveRx Corporation.

DiscoveRx completed the acquisition of KINOMEscan kinase screening services division from Ambit Biosciences in 2010 and continues to invest heavily in the development of this key technology platform.

About DiscoveRx

Founded in 2000, DiscoveRx is a privately held, venture-backed company headquartered in Fremont, California, with additional offices in San Diego, California and Birmingham, England. The Company pioneered the use of β-galactosidase enzyme fragment complementation in biochemical and cell based assays for discovery research in fields of receptor biology, and holds extensive intellectual property in this area. DiscoveRx is dedicated to the development and commercialization of innovative solutions to study GPCRs, kinases and other major drug target classes, and many of their innovative products and solutions have been widely adopted in academic, pharmaceutical and biotech drug screening laboratories worldwide. In October 2010, it completed its acquisition of the KINOMEscan division ( of Ambit Biosciences thereby becoming a key solution provider for kinase drug discovery profiling and screening. The Company is also a recipient of multiple Frost and Sullivan awards. For more information on DiscoveRx products and services, please visit


DiscoveRx Corp.
Sailaja Kuchibhatla, 1-510-979-1415
Sr. VP Business Development

KEYWORDS:   United Kingdom  United States  Europe  North America  California

INDUSTRY KEYWORDS:   Health  Biotechnology  Genetics  Pharmaceutical



Suggested Articles

Eli Lilly is combining the oncology team at Lilly Research Laboratories with Loxo Oncology and putting a trio of Loxo execs at the helm.

The failure of SAGE-217 to beat placebo wiped more than 50% off Sage’s share price as investors digested the implications of the data.

The data tee Aurinia up to file for FDA approval next year and go on to address a major unmet medical need.